{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:03:09Z","timestamp":1774526589361,"version":"3.50.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>West Virginia has high rates of opioid-related health crises and deaths that extend to pregnant women and newborns. Our institutional screening approach has included universal umbilical cord tissue drug analysis (UCTDA) since 2013. The objective of this study was to retrospectively report incidence of in utero drug exposure using UCTDA data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Two sequential UCTDA data sets (October 2013 to September 2015, and October 2016 to September 2018) represent interrupted epochs given changes in interfaced data availability. UCTDA positivity (by drug class and parent drug) and numbers of drugs detected in each specimen were retrospectively analyzed. THC was removed from the analysis because of discontinuous testing, and 4 opioids were separated from the data set given the potential for both therapeutic and illicit use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>UCTDA specimens that were positive for drugs (22% overall) decreased between Epochs 1 and 2, from 25% to 20%. Increased positivity was noted for hydrocodone (+407%), oxycodone (+240%), amphetamines (+506%), and cocaine (+417%). Fentanyl and morphine positivity decreased by 75% and 18%, respectively, whereas buprenorphine detection increased 195%. Most positive specimens (80% overall) had 1 drug present, but specimens positive for 2 to 6 discrete drugs were found.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Universal UCTDA allows for unbiased assessment of drug exposure in infants. With the additional knowledge of therapeutic indications for drug use, UCTDA may allow for analysis of trends in illicit drug use and the impact of interventions to curb neonatal abstinence syndrome.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jalm\/jfaa196","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T19:12:22Z","timestamp":1603221142000},"page":"285-297","source":"Crossref","is-referenced-by-count":9,"title":["Drug Positivity Findings from a Universal Umbilical Cord Tissue Drug Analysis Program in Appalachia"],"prefix":"10.1093","volume":"6","author":[{"given":"Panitan","family":"Yossuck","sequence":"first","affiliation":[{"name":"Department of Pediatrics, West Virginia University School of Medicine, Morgantown, WV"},{"name":"Department of Pathology, Anatomy, and Laboratory Medicine, West Virginia University School of Medicine, Morgantown, WV"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danyel H","family":"Tacker","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, West Virginia University School of Medicine, Morgantown, WV"},{"name":"Department of Pathology, Anatomy, and Laboratory Medicine, West Virginia University School of Medicine, Morgantown, WV"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"2021011315450227400_jfaa196-B1","year":"2017"},{"key":"2021011315450227400_jfaa196-B2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1037\/a0021741","article-title":"Drug use during pregnancy: validating the drug abuse screening test against physiological measures","volume":"24","author":"Grekin","year":"2010","journal-title":"Psychol Addict Behav"},{"key":"2021011315450227400_jfaa196-B3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2105\/AJPH.76.6.667","article-title":"Maternal marijuana use and neonatal outcome: uncertainty posed by self-reports","volume":"76","author":"Hingson","year":"1986","journal-title":"Am J Public Health"},{"key":"2021011315450227400_jfaa196-B4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1542\/peds.107.2.309","article-title":"The Maternal Lifestyle Study: drug use by meconium toxicology and maternal self-report","volume":"107","author":"Lester","year":"2001","journal-title":"Pediatrics"},{"key":"2021011315450227400_jfaa196-B5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1542\/peds.89.1.107","article-title":"Drug screening of newborns by meconium analysis: a large-scale, prospective, epidemiologic study","volume":"89","author":"Ostrea","year":"1992","journal-title":"Pediatrics"},{"key":"2021011315450227400_jfaa196-B6","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1097\/AOG.0000000000002235","article-title":"ACOG Committee opinion: opioid use and opioid use disorder in pregnancy","volume":"130","year":"2017","journal-title":"Obstetrics Gynecol"},{"key":"2021011315450227400_jfaa196-B7","doi-asserted-by":"crossref","first-page":"e020248","DOI":"10.1136\/bmjopen-2017-020248","article-title":"Comparison and validation of screening tools for substance use in pregnancy: a cross-sectional study conducted in Maryland prenatal clinics","volume":"8","author":"Coleman-Cowger","year":"2018","journal-title":"BMJ Open"},{"key":"2021011315450227400_jfaa196-B8","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/jp.2015.36","article-title":"Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012","volume":"35","author":"Patrick","year":"2015","journal-title":"J Perinatol"},{"key":"2021011315450227400_jfaa196-B9","doi-asserted-by":"crossref","first-page":"799","DOI":"10.15585\/mmwr.mm6531a2","article-title":"Incidence of neonatal abstinence syndrome\u201428 states, 1999\u20132013","volume":"65","author":"Ko","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021011315450227400_jfaa196-B10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1542\/hpeds.2017-0077","article-title":"Hospital variation in neonatal abstinence syndrome incidence, treatment modalities, resource use, and costs across pediatric hospitals in the United States, 2013 to 2016","volume":"8","author":"Milliren","year":"2018","journal-title":"Hosp Pediatr"},{"key":"2021011315450227400_jfaa196-B11","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1056\/NEJMsa1500439","article-title":"Increasing incidence of the neonatal abstinence syndrome in US neonatal ICUs","volume":"372","author":"Tolia","year":"2015","journal-title":"N Engl J Med"},{"key":"2021011315450227400_jfaa196-B12","doi-asserted-by":"crossref","first-page":"e20173520","DOI":"10.1542\/peds.2017-3520","article-title":"Incidence and costs of neonatal abstinence syndrome among infants with Medicaid: 2004\u20132014","volume":"141","author":"Winkelman","year":"2018","journal-title":"Pediatrics"},{"key":"2021011315450227400_jfaa196-B13","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamapediatrics.2016.2150","article-title":"Rates of neonatal abstinence syndrome amid efforts to combat the opioid abuse epidemic","volume":"170","author":"Brown","year":"2016","journal-title":"JAMA Pediatr"},{"key":"2021011315450227400_jfaa196-B14","doi-asserted-by":"crossref","first-page":"e20170900","DOI":"10.1542\/peds.2017-0900","article-title":"Ohio Perinatal Quality Collaborative improves care of neonatal narcotic abstinence syndrome","volume":"141","author":"Walsh","year":"2018","journal-title":"Pediatrics"},{"key":"2021011315450227400_jfaa196-B15","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.2012.3951","article-title":"Neonatal abstinence syndrome and associated health care expenditures: United States, 2000\u20132009","volume":"307","author":"Patrick","year":"2012","journal-title":"JAMA"},{"key":"2021011315450227400_jfaa196-B16","first-page":"14","article-title":"Buprenorphine: a new player in neonatal withdrawal syndrome","volume":"111","author":"Nanda","year":"2015","journal-title":"W V Med J"},{"key":"2021011315450227400_jfaa196-B17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.clinbiochem.2016.11.026","article-title":"Evaluating a switch from meconium to umbilical cord tissue for newborn drug testing: a retrospective study at an academic medical center","volume":"50","author":"Palmer","year":"2017","journal-title":"Clin Biochem"},{"key":"2021011315450227400_jfaa196-B18","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.clinbiochem.2017.03.006","article-title":"Comparison of umbilical cord tissue and meconium for the confirmation of in utero drug exposure","volume":"50","author":"Colby","year":"2017","journal-title":"Clin Biochem"},{"key":"2021011315450227400_jfaa196-B19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.jp.7211416","article-title":"Testing for fetal exposure to illicit drugs using umbilical cord tissue vs meconium","volume":"26","author":"Montgomery","year":"2006","journal-title":"J Perinatol"},{"key":"2021011315450227400_jfaa196-B20","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1542\/peds.2011-3212","article-title":"Neonatal drug withdrawal","volume":"129","author":"Hudak","year":"2012","journal-title":"Pediatrics"},{"key":"2021011315450227400_jfaa196-B21","first-page":"48","article-title":"Prevalence of drug use in pregnant West Virginia patients","volume":"106","author":"Stitely","year":"2010","journal-title":"WV Med J"},{"key":"2021011315450227400_jfaa196-B22","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jpeds.2014.10.004","article-title":"Universal maternal drug testing in a high-prevalence region of prescription opiate abuse","volume":"166","author":"Wexelblatt","year":"2015","journal-title":"J Pediatr"},{"key":"2021011315450227400_jfaa196-B23","author":"Smith"},{"key":"2021011315450227400_jfaa196-B24","year":"2020"},{"key":"2021011315450227400_jfaa196-B25","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/AOG.0000000000002579","article-title":"Prescription and other medication use in pregnancy","volume":"131","author":"Haas","year":"2018","journal-title":"Obstet Gynecol"},{"key":"2021011315450227400_jfaa196-B26","year":"2013"},{"key":"2021011315450227400_jfaa196-B27","year":"2017"},{"key":"2021011315450227400_jfaa196-B28","year":"2014"},{"key":"2021011315450227400_jfaa196-B29","author":"Haarbauer","year":"2019"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jalm\/article-pdf\/6\/1\/285\/35721708\/jfaa196.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jalm\/article-pdf\/6\/1\/285\/35721708\/jfaa196.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T01:40:58Z","timestamp":1669254058000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/6\/1\/285\/6038931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12,16]]},"published-print":{"date-parts":[[2021,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfaa196","relation":{},"ISSN":["2576-9456","2475-7241"],"issn-type":[{"value":"2576-9456","type":"print"},{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1]]},"published":{"date-parts":[[2020,12,16]]}}}